Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly

Hormone and Metabolic Research

Volumn 45, Issue 4, 2013, Pages 314-318

  Anagnostis, P ^a   Efstathiadou, Z A ^a   Gougoura, S ^b   Polyzos, S A ^c   Karathanasi, E ^a   Dritsa, P ^b   Kita, M ^a   Koukoulis, G N ^b  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

acromegaly; catalase; glutathione; nitric oxide; oxidative stress; total antioxidant capacity

Indexed keywords

CATALASE; GLUTATHIONE; GLUTATHIONE DERIVATIVE; NITRIC OXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TOTAL OXIDIZED GLUTATHIONE; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; SMOKING;

ACROMEGALY; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CATALASE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84876866746     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1323765     Document Type: Article

References (19)

1. Berg C., Petersenn S., Lahner H., Herrmann B. L., Buchfelder M., Droste M., Stalla G. K., Strasburger C. J., Roggenbuck U., Lehmann N., Moebus S., Jöckel K. H., Möhlenkamp S., Erbel R., Saller B., Mann K. Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab: 2010; 95 3648 3656
2. Kondo T., Hirose M., Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb: 2009; 16 532 538
3. Andersson I. J., Johansson M. E., Wickman A., Bohlooly-Y M., Klintland N., Caidahl K., Gustafsson M., Borén J., Gan L. M., Bergström G. Endothelial dysfunction in growth hormone transgenic mice. Clin Sci (Lond): 2006; 110 217 225 (Pubitemid 43241483)
4. Ronconi V., Giacchetti G., Mariniello B., Camilletti A., Mantero F., Boscaro M., Vignini A., Mazzanti L. Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press: 2005; 14 227 232 (Pubitemid 41387812)
5. Paisley A. N., Izzard A. S., Gemmell I., Cruickshank K., Trainer P. J., Heagerty A. M. Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab: 2009; 94 1111 1117
6. Boero L., Cuniberti L., Magnani N., Manavela M., Yapur V., Bustos M., Rosso L. G., Meroño T., Marziali L., Viale L., Evelson P., Negri G., Brites F. Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (Oxf): 2010; 72 654 660
7. Yarman S., Ozden T. A., Gokkusu C. The evaluation of lipid peroxidation and acute effect of octreotide on lipid peroxidation in patients with active acromegaly. Clin Chim Acta: 2003; 336 45 48 (Pubitemid 37324752)
8. Anagnostis P., Efstathiadou Z. A., Polyzos S. A., Adamidou F., Slavakis A., Sapranidis M., Litsas I. D., Katergari S., Selalmatzidou D., Kita M. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract: 2011; 65 896 902
9. Giustina A., Chanson P., Bronstein M. D., Klibanski A., Lamberts S., Casanueva F. F., Trainer P., Ghigo E., Ho K., Melmed S. Acromegaly Consensus Group A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab: 2010; 95 3141 3148
10. Gougoura S., Nikolaidis M. G., Kostaropoulos I. A., Jamurtas A. Z., Koukoulis G., Kouretas D. Increased oxidative stress indices in the blood of child swimmers. Eur J Appl Physiol: 2007; 100 235 239 (Pubitemid 46681643)
11. Clayton R. N. Cardiovascular function in acromegaly. Endocr Rev: 2003; 24 272 277 (Pubitemid 36724370)
12. Muller G., Goettsch C., Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie: 2007; 27 5 12 (Pubitemid 46280045)
13. Muller G., Morawietz H. NAD(P)H oxidase and endothelial dysfunction. Horm Metab Res: 2009; 41 152 158
14. Ignarro L. J. Physiology and pathophysiology of nitric oxide. Kidney Int: 1996; 55 Suppl S2 S5
15. Markussis V., Beshyah S. A., Fisher C., Parker K. H., Nicolaides A. N., Johnston D. G. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur J Endocrinol: 1997; 136 157 164 (Pubitemid 27096344)
16. Meng D., Shi X., Jiang B. H., Fang J. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med: 2007; 42 1651 1660 (Pubitemid 46617145)
17. Repetto M., Reides C., Gomez Carretero M. L., Costa M., Griemberg G., Llesuy S. Oxidative stress in blood of HIV infected patients. Clin Chim Acta: 1996; 255 107 117 (Pubitemid 26374053)
18. Sesmilo G., Fairfield W. P., Katznelson L., Pulaski K., Freda P. U., Bonert V., Dimaraki E., Stavrou S., Vance M. L., Hayden D., Klibanski A. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab: 2002; 87 1692 1699 (Pubitemid 34615258)
19. Delaroudis S. P., Efstathiadou Z. A., Koukoulis G. N., Kita M. D., Farmakiotis D., Dara O. G., Goulis D. G., Makedou A., Makris P., Slavakis A., Avramides A. I. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf): 2008; 69 279 284. (Pubitemid 352009020)